No. 004 · Repair · Healing Peptide
GHK-Cu
Also known as: GHK-CuCopper tripeptide-1Copper peptidePrezatide copper
- Not FDA approved
- WADA ✗ S0
2D structure from PubChem CID 71587328 (Prezatide copper), matched by exact name. Hydrogens on carbon are implied.
No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.
Quick answers
- What is GHK-Cu?
- A naturally occurring copper peptide with powerful skin-remodeling and wound-healing properties. Copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine.
- How strong is the evidence for GHK-Cu?
- Tier B (small human studies) on the peptidemeta evidence scale. Human data consist of small topical cosmetic/skin studies; most mechanistic evidence is in vitro and animal.
- Is GHK-Cu FDA-approved?
- No. GHK-Cu is not approved by the FDA for any use. Used as a cosmetic ingredient; not an approved drug.
- Is GHK-Cu banned in sport?
- Yes. GHK-Cu is prohibited in sport by the World Anti-Doping Agency under S0 (non-approved substances).
- How does GHK-Cu work?
- GHK-Cu chelates copper(II) ions and delivers them to tissues, activating metalloproteinases that remodel the extracellular matrix. It stimulates collagen I, III, and V synthesis, promotes decorin and glycosaminoglycan production, and upregulates DNA repair genes while suppressing pro-inflammatory cytokines like TGF-beta.
- What is known about the safety of GHK-Cu?
- Well-tolerated both topically and via injection with decades of cosmetic use. Mild injection site redness reported.
Last reviewed · editorial policy · markdown
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
TIER B — Human data limited to small, open-label or pharmacokinetic studies.
Human data consist of small topical cosmetic/skin studies; most mechanistic evidence is in vitro and animal.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Discovered
- 1973 GHK identified in human plasma by Loren Pickart.
- Routes studied
- Subcutaneous, Topical, Intramuscular Routes used in published research
- FDA
- Not approved Used as a cosmetic ingredient; not an approved drug.
- WADA
- Prohibited · S0 Non-approved substances
Overview
A naturally occurring copper peptide with powerful skin-remodeling and wound-healing properties. It stimulates collagen synthesis and promotes dermal repair at the cellular level.
Research status Well-studied copper peptide with decades of published dermatology research; available in approved cosmetic formulations
Mechanism
GHK-Cu chelates copper(II) ions and delivers them to tissues, activating metalloproteinases that remodel the extracellular matrix. It stimulates collagen I, III, and V synthesis, promotes decorin and glycosaminoglycan production, and upregulates DNA repair genes while suppressing pro-inflammatory cytokines like TGF-beta.
Effects reported in research
Reported outcomes, not promises. Human data are limited to small studies, and many of these findings are preclinical.
- Stimulated collagen and elastin production
- Improved skin firmness and elasticity
- Accelerated wound healing
- Reduced fine lines and hyperpigmentation
Safety & unknowns
Well-tolerated both topically and via injection with decades of cosmetic use. Mild injection site redness reported. Avoid in Wilson disease or copper metabolism disorders. Not FDA-approved as a drug; available in cosmetic formulations.
Unknowns. No randomized controlled trials have been published. Small studies cannot detect uncommon or long-term harms.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [0]
No studies cited for this entry yet.
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- Pickart & Margolina 2018, Int J Mol Sci (review) pubmed.ncbi.nlm.nih.gov
- PubMed: GHK-Cu pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List wada-ama.org
Cite this entry
peptidemeta. (2026). GHK-Cu. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/ghk-cu/
@misc{peptidemeta-ghk-cu,
title = {GHK-Cu},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/ghk-cu/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.